cycle

(redirected from Visual cycle)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia, Wikipedia.

cycle

noun age, alternation, circle, circuit, consecution, course, eon, epoch, era, flow, period, recurrence, recurring period, regular return, regglarity of recurrence, repetitiveness, revolution, rotation, round, sequence, succession
See also: annum, frequency, life, sequence, succession
References in periodicals archive ?
ACU-4429 is Acucela's novel, small-molecule visual cycle modulator (VCM) being developed to treat dry age-related macular degeneration (dry AMD), which occurs when light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.
EDT) Poster Title: A Phase 1 Dose-Ranging Study of ACU-4429, a Novel Visual Cycle Modulator, in Healthy Volunteers Program#/Poster#: 2043/D1061, Session 267 Location: Hall B/C
He will present an overview of the Company's visual cycle modulation (VCM) technology for dry-age related macular degeneration (AMD), which will begin at 4:03 p.
a Washington State-based clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced that data for ACU-4429, the Company's novel, small-molecule visual cycle modulator (VCM) for the treatment of dry age-related macular degeneration (dry AMD), will be highlighted at the 10th International Symposium on Ocular Pharmacology and Therapeutics (ISOPT) being held in Vienna, Austria from December 1-4, 2011.
ACU-4429 utilizes Acucela's proprietary visual cycle modulation technology, and is designed to prevent or inhibit the generation of toxic by-products of the visual cycle that can lead to degenerative eye conditions such as dry AMD.
One of Acucela's lead compounds is an oral visual cycle modulator (VCM), ACU-4429, and is currently in Phase 2 clinical trials for dry age-related macular degeneration (AMD).
a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, today announced the publication of a new paper in Retina: The Journal of Retinal and Vitreous Diseases evaluating the safety and tolerability of ACU-4429, a novel, small-molecule visual cycle modulator (VCM).